Dr Mazen Noureddin explains how PCPs can identify MASH patients with fibrosis who may benefit from liver-directed therapy, while maintaining lifestyle and metabolic care.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep5-2026a1000aax. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview

Hepatic Thyroid Hormone Receptor-β Signalling: Mechanisms and Recent Advancements in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/39658733/

Cardiovascular-Kidney-Metabolic (CKM) Syndrome https://emedicine.medscape.com/article/165124-overview

Diagnostic Performance of Circulating Biomarkers for Non-Alcoholic Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/37679433/

The Role of Fibroscan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/

Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/37632072/

FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis

MELD 3.0 in Advanced Chronic Liver Disease https://pubmed.ncbi.nlm.nih.gov/37751367/

The Enhanced Liver Fibrosis (ELF) Test in Diagnosis and Management of Liver Fibrosis https://pubmed.ncbi.nlm.nih.gov/30526098/

Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial https://pubmed.ncbi.nlm.nih.gov/41127972/

Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance https://pubmed.ncbi.nlm.nih.gov/39422487/

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis https://pubmed.ncbi.nlm.nih.gov/39038768/

Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations https://pubmed.ncbi.nlm.nih.gov/42483637/

FDA Accelerated Approval Program https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH https://pubmed.ncbi.nlm.nih.gov/34670042/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs VanWagner and Chen discuss whether fatty liver is reversible, weight-loss targets, diet quality, exercise, and where GLP-1s and bariatric surgery fit into MASLD treatment.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep4-2026a1000aaw. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview

Two-Year Mediterranean Diet Intervention Improves Hepatic Health in MASLD Patients https://pubmed.ncbi.nlm.nih.gov/40428516/

An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans https://pubmed.ncbi.nlm.nih.gov/29456073/

Intermittent Fasting Improves Hepatic End Points in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/37534936/

Effect of 5:2 Intermittent Fasting Diet Versus Daily Calorie Restriction Eating on Metabolic-Associated Fatty Liver Disease — A Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/39229586/

Physical Activity Compared to Adiposity and Risk of Liver-Related Mortality: Results From Two Prospective, Nationwide Cohorts https://pubmed.ncbi.nlm.nih.gov/31954204/

Adult Activity: An Overview https://www.cdc.gov/physical-activity-basics/guidelines/adults.html

Positive Effects of Exercise Intervention Without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34579012/

Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/39896971/

Bariatric Surgery Reduces Long-Term Mortality in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis https://pubmed.ncbi.nlm.nih.gov/39541951/

Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications https://pubmed.ncbi.nlm.nih.gov/41153720/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep3-2026a1000aav. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview

MetALD: Clinical Aspects, Pathophysiology and Treatment https://pubmed.ncbi.nlm.nih.gov/39897615/

Cirrhosis https://emedicine.medscape.com/article/185856-overview

The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/

Magnetic Resonance Elastography of the Liver: Everything You Need to Know to Get Started https://pmc.ncbi.nlm.nih.gov/articles/PMC9538666/

A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/39131248/

Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis https://pmc.ncbi.nlm.nih.gov/articles/PMC11240480/

Viral Hepatitis https://emedicine.medscape.com/article/775507-overview

Autoimmune Hepatitis (AIH) https://emedicine.medscape.com/article/172356-overview

FibroSURE as a Noninvasive Marker of Liver Fibrosis and Inflammation in Chronic Hepatitis B https://pubmed.ncbi.nlm.nih.gov/24990385/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep2-2026a1000aau. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review https://pubmed.ncbi.nlm.nih.gov/28100008/

Practical Guide, Challenges, and Pitfalls in Liver Fibrosis Staging https://pubmed.ncbi.nlm.nih.gov/37536882/

Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/29378307/

A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature https://pubmed.ncbi.nlm.nih.gov/37363821/

Phosphatidylethanol in Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/40759197/

Phosphatidylethanol and Self-Reported Alcohol Intake to Subclassify Individuals at Risk of Steatotic Liver Disease: An Analysis of Data From a Prospective Cohort Study https://pubmed.ncbi.nlm.nih.gov/40945520/

The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test https://pubmed.ncbi.nlm.nih.gov/9738608/

Elevated ALT/AST Ratio as a Marker for NAFLD Risk and Severity: Insights From a Cross-Sectional Analysis in the United States https://pubmed.ncbi.nlm.nih.gov/39253584/

Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5 https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm

Wilson Disease https://emedicine.medscape.com/article/183456-overview

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36626630/

AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/36727674/

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41812830/

FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis

Noninvasive Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41640956/

NAFLD: Reporting Histologic Findings in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/33111374/

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study https://pubmed.ncbi.nlm.nih.gov/37127100/

Cause-Specific Mortality in 13,099 Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease in Sweden https://pubmed.ncbi.nlm.nih.gov/40139508/

Liver Function Tests https://www.ncbi.nlm.nih.gov/books/NBK482489/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.